Lars Zender
YOU?
Author Swipe
View article: Correction: An analysis of the distribution of bone and soft tissue sarcoma diagnoses and their disparities in Southwest Germany: a multicenter approach
Correction: An analysis of the distribution of bone and soft tissue sarcoma diagnoses and their disparities in Southwest Germany: a multicenter approach Open
[This corrects the article DOI: 10.3389/fonc.2025.1592004.].
View article: An analysis of the distribution of bone and soft tissue sarcoma diagnoses and their disparities in Southwest Germany: a multicenter approach
An analysis of the distribution of bone and soft tissue sarcoma diagnoses and their disparities in Southwest Germany: a multicenter approach Open
Introduction Sarcoma is a rare and highly heterogeneous family of mesenchymal tumors. The experience and interdisciplinary approach of specialized high-volume sarcoma centers has a significant impact on disease treatment and outcome for pa…
View article: Variability of Metabolic Rate and Distribution Volume Quantification in Whole-Body Parametric PATLAK [18F]-FDG PET/CT—A Prospective Trial in Patients with Lung Cancer
Variability of Metabolic Rate and Distribution Volume Quantification in Whole-Body Parametric PATLAK [18F]-FDG PET/CT—A Prospective Trial in Patients with Lung Cancer Open
Background: The recent introduction of whole-body positron emission tomography/ computed tomography (PET/CT) scanners and multi-bed, multi-time point acquisition technique enable calculating fluorodeoxyglucose (FDG) kinetics in the whole b…
View article: Uncovering α-Selectivity for Liver X Receptor Agonists for Lipotoxic Cancer Therapies
Uncovering α-Selectivity for Liver X Receptor Agonists for Lipotoxic Cancer Therapies Open
Hepatocellular carcinoma (HCC) is one of the most frequent causes of cancer-related deaths worldwide. We recently showed that pharmacologically induced lipotoxicity represents a promising therapeutic strategy for the treatment of HCC. Synt…
View article: First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer
First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer Open
Colorectal cancer (CRC) constitutes the second leading cause of cancer-related death worldwide and advanced CRCs are resistant to targeted therapies, chemotherapies and immunotherapies. p38α ( Mapk14 ) has been suggested as a therapeutic t…
View article: SarkoLife: quality of life in patients undergoing multimodal soft tissue sarcoma treatment
SarkoLife: quality of life in patients undergoing multimodal soft tissue sarcoma treatment Open
Objective To assess the tolerability of multimodal therapy in soft tissue sarcoma patients, particularly with regard to their quality of life and level of distress. Materials and methods A retrospective cohort study enrolled individuals re…
View article: PSMA-Guided Imaging and Therapy of Advanced Adenoid Cystic Carcinomas and Other Salivary Gland Carcinomas
PSMA-Guided Imaging and Therapy of Advanced Adenoid Cystic Carcinomas and Other Salivary Gland Carcinomas Open
SGCs are rare malignancies, accounting for less than 1% of all head and neck cancers [...]
View article: Regulation of KIF23 by miR-107 controls replicative tumor cell fitness in mouse and human hepatocellular carcinoma
Regulation of KIF23 by miR-107 controls replicative tumor cell fitness in mouse and human hepatocellular carcinoma Open
Our study revealed the central role of the miR-107/KIF23 axis in controlling tumor cell fitness and hepatocellular carcinoma progression. The results demonstrate that the overexpression of miR-107 or silencing of its target, KIF23, markedl…
View article: A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine
A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine Open
Current treatment outcome of patients with glioblastoma (GBM) remains poor. Following standard therapy, recurrence is universal with limited survival. Tumors from 173 GBM patients are analysed for somatic mutations to generate a personaliz…
View article: Titration of RAS alters senescent state and influences tumour initiation
Titration of RAS alters senescent state and influences tumour initiation Open
View article: Author Correction: mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype
Author Correction: mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype Open
View article: First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure
First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure Open
View article: Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in <i>KRAS</i> -mutant cancers
Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in <i>KRAS</i> -mutant cancers Open
The Kirsten rat sarcoma viral oncogene homologue KRAS is among the most commonly mutated oncogenes in human cancers, thus representing an attractive target for precision oncology. The approval for clinical use of the first selective inhibi…
View article: Clinical management of NUT carcinoma (NC) in Germany: Analysis of survival, therapy response, tumor markers and tumor genome sequencing in 35 adult patients
Clinical management of NUT carcinoma (NC) in Germany: Analysis of survival, therapy response, tumor markers and tumor genome sequencing in 35 adult patients Open
View article: Radiosensitizing Favors Response to Peptide Receptor Radionuclide Therapy in Patients With Highly Proliferative Neuroendocrine Malignancies
Radiosensitizing Favors Response to Peptide Receptor Radionuclide Therapy in Patients With Highly Proliferative Neuroendocrine Malignancies Open
Aim/Introduction Peptide receptor radionuclide therapy (PRRT) represents a cornerstone of treatment regimens for patients with low proliferative neuroendocrine tumors (NETs). However, in patients experiencing somatostatin receptor–positive…
View article: Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3
Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3 Open
Introduction Neuroendocrine neoplasms (NEN) are a rare and heterogenous group of tumors arising from neuroendocrine cells in multiple organs. Neuroendocrine tumors (NET) G3 encompass a small subgroup accounting for less than 10% of all neu…
View article: KIF23 regulation by miR-107 controls replicative tumor cell fitness in mouse and human hepatocellular carcinoma
KIF23 regulation by miR-107 controls replicative tumor cell fitness in mouse and human hepatocellular carcinoma Open
Background & Aims In hepatocellular carcinoma, there is a lack of successful translation of experimental targets identified in mouse models to human patients. In this study, we used a comprehensive transcriptomic approach in mice to identi…
View article: 1016O Autoimmunity against surfactant protein B drives immune checkpoint inhibitor-related pneumonitis in patients with NSCLC
1016O Autoimmunity against surfactant protein B drives immune checkpoint inhibitor-related pneumonitis in patients with NSCLC Open
View article: Myasthenia gravis as initial presentation of a pancreatic neuroendocrine tumor: A case report
Myasthenia gravis as initial presentation of a pancreatic neuroendocrine tumor: A case report Open
Myasthenia gravis (MG) is a heterogeneous autoimmune disease, which is characterized by a postsynaptic neuromuscular transmission defect, with antibodies directly targeting the acetylcholine receptor (AChR) or other structural proteins of …
View article: Diagnostic Approaches for Neuroendocrine Neoplasms of Unknown Primary (NEN-UPs) and Their Prognostic Relevance—A Retrospective, Long-Term Single-Center Experience
Diagnostic Approaches for Neuroendocrine Neoplasms of Unknown Primary (NEN-UPs) and Their Prognostic Relevance—A Retrospective, Long-Term Single-Center Experience Open
Neuroendocrine neoplasms (NENs) represent a rare and heterogenous group of tumors with predominantly gastroenteropancreatic or pulmonary origin. Despite numerous diagnostic efforts, the primary tumor site remains unknown in up to 20% of th…
View article: Diagnostic Performance of Dynamic Whole-Body Patlak [18F]FDG-PET/CT in Patients with Indeterminate Lung Lesions and Lymph Nodes
Diagnostic Performance of Dynamic Whole-Body Patlak [18F]FDG-PET/CT in Patients with Indeterminate Lung Lesions and Lymph Nodes Open
Background: Static [18F]FDG-PET/CT is the imaging method of choice for the evaluation of indeterminate lung lesions and NSCLC staging; however, histological confirmation of PET-positive lesions is needed in most cases due to its limited sp…
View article: Long-term prognostic factors for PRRT in neuroendocrine tumors
Long-term prognostic factors for PRRT in neuroendocrine tumors Open
Aim/introduction Peptide receptor radionuclide therapy (PRRT) is an effective and well-tolerated treatment option for patients with neuroendocrine tumors (NETs) that prolongs progression-free survival (PFS). However, the limited overall su…
View article: Design and Optimization of Novel Benzimidazole- and Imidazo[4,5-<i>b</i>]pyridine-Based ATM Kinase Inhibitors with Subnanomolar Activities
Design and Optimization of Novel Benzimidazole- and Imidazo[4,5-<i>b</i>]pyridine-Based ATM Kinase Inhibitors with Subnanomolar Activities Open
The ATM kinase is a promising target in cancer treatment as an important regulator of the cellular response to DNA double-strand breaks. In this work, we present a new class of specific benzimidazole-based ATM inhibitors with picomolar pot…
View article: Loss of the cyclin kinase inhibitor p27kip1 opens atherapeutic window by deregulating pathway choiceafter DNA double strand breaks
Loss of the cyclin kinase inhibitor p27kip1 opens atherapeutic window by deregulating pathway choiceafter DNA double strand breaks Open
Reduced expression of the cyclin kinase inhibitor p27kip1 is found in many human tumors and correlates with inferior prognosis. We tested the importance of p27 loss for the induction of genetic instability in Notch driven cholangiocarcinom…
View article: Titration of oncogenic RAS alters senescent state and influences tumour initiation
Titration of oncogenic RAS alters senescent state and influences tumour initiation Open
Oncogenic RAS-induced senescence (OIS) is an autonomous tumour suppressor mechanism associated with pre-malignancy1-3. Achieving this phenotype typically requires a high level of oncogenic stress, yet the phenotype provoked by l…
View article: Figure S8 from MYC- and MIZ1-Dependent Vesicular Transport of Double-Strand RNA Controls Immune Evasion in Pancreatic Ductal Adenocarcinoma
Figure S8 from MYC- and MIZ1-Dependent Vesicular Transport of Double-Strand RNA Controls Immune Evasion in Pancreatic Ductal Adenocarcinoma Open
TBK1-dependent regulation of NF-kB-dependent gene expression.
View article: 44d_RNAseq_data from A Pro-Regenerative Environment Triggers Premalignant to Malignant Transformation of Senescent Hepatocytes
44d_RNAseq_data from A Pro-Regenerative Environment Triggers Premalignant to Malignant Transformation of Senescent Hepatocytes Open
44d post hepatectomy RNAseq count and metadata files
View article: Figure S3 from MYC- and MIZ1-Dependent Vesicular Transport of Double-Strand RNA Controls Immune Evasion in Pancreatic Ductal Adenocarcinoma
Figure S3 from MYC- and MIZ1-Dependent Vesicular Transport of Double-Strand RNA Controls Immune Evasion in Pancreatic Ductal Adenocarcinoma Open
Characterization of MYC depletion.
View article: Data from MYC- and MIZ1-Dependent Vesicular Transport of Double-Strand RNA Controls Immune Evasion in Pancreatic Ductal Adenocarcinoma
Data from MYC- and MIZ1-Dependent Vesicular Transport of Double-Strand RNA Controls Immune Evasion in Pancreatic Ductal Adenocarcinoma Open
Deregulated expression of the MYC oncoprotein enables tumor cells to evade immune surveillance, but the mechanisms underlying this surveillance are poorly understood. We show here that endogenous MYC protects pancreatic ductal adenocarcino…
View article: Figure S2 from MYC- and MIZ1-Dependent Vesicular Transport of Double-Strand RNA Controls Immune Evasion in Pancreatic Ductal Adenocarcinoma
Figure S2 from MYC- and MIZ1-Dependent Vesicular Transport of Double-Strand RNA Controls Immune Evasion in Pancreatic Ductal Adenocarcinoma Open
Histological analyses of transplanted tumors.